Zepbound® contains tirzepatide, a prescription medicine that activates two hormone pathways: GIP and GLP-1. By engaging these receptors, tirzepatide helps regulate appetite and metabolism. Many people experience reduced hunger, improved fullness after meals, and better control over cravings - supporting meaningful, sustained weight reduction when combined with lifestyle changes.
Zepbound® is injected subcutaneously (under the skin) once weekly, on the same day each week, at any time of day, with or without food.Common injection sites include:
Rotate injection sites each week and avoid injecting into skin that is tender, bruised, red, or hard. Use Zepbound® exactly as prescribed and keep regular follow-ups—your clinician may adjust your dose over time to support tolerability and results.
Common side effects may include:
• Nausea
• Diarrhea
• Vomiting
• Constipation
• Decreased appetite
• Injection site reactions
More serious side effects are possible. This medication is not appropriate for individuals with certain medical conditions. A full medical evaluation is required prior to starting treatment.
Zepbound® is a prescription medicine containing tirzepatide used for long-term weight management in eligible adults, together with nutrition and activity changes. It is designed for consistent, ongoing use under clinician guidance—because sustainable weight reduction is typically a long-term plan, not a short-term fix.
Tirzepatide activates two hormone pathways—GIP and GLP-1. By engaging both receptors, it can support weight reduction by helping to:
This dual-action mechanism is designed to support meaningful and sustained weight reduction when paired with lifestyle changes.
Zepbound® is injected once per week, on the same day each week, with or without food. Injection sites include the abdomen, thigh, or upper arm. Consistency matters—staying on schedule and rotating sites can help support comfort and routine.Regular clinician follow-up is important to monitor progress, manage side effects, and adjust dosage if needed for safe, effective use.
Zepbound® is a brand-name prescription injection containing tirzepatide. It’s FDA‑approved for chronic weight management in adults with obesity or overweight with certain weight‑related conditions, as part of a reduced‑calorie diet and increased physical activity.
Tirzepatide activates two hormone pathways (GIP and GLP‑1) involved in appetite regulation and metabolic control. This can help reduce hunger, increase fullness, and support lower calorie intake over time.
Eligibility is determined by a licensed clinician based on factors such as BMI, weight‑related health conditions, medical history, and medication safety. It may not be appropriate for people with certain thyroid conditions, a history of pancreatitis, or those who are pregnant or planning pregnancy.
Some people notice appetite changes in the first few weeks. Weight changes typically become more noticeable over 8–12 weeks and may continue as the dose is adjusted for tolerability and results.
Yes. Clinicians usually start at a lower dose and increase gradually to reduce side effects. Your dose and titration schedule are individualized based on how you respond and tolerate the medication.
The most common side effects are gastrointestinal—nausea, diarrhea, constipation, vomiting, stomach discomfort, and reduced appetite—especially during dose increases. Many people find symptoms improve as the body adapts.
Seek urgent medical care for severe or persistent abdominal pain, signs of an allergic reaction, repeated vomiting with dehydration, or symptoms of very low blood sugar (especially if you take insulin or sulfonylureas). Always contact your clinician if anything feels concerning.
Zepbound is taken as a once‑weekly subcutaneous injection. Your clinician will provide instructions for injection technique, site rotation, storage, and what to do if you travel or change your dosing day.
If you miss an injection, follow your clinician’s instructions and the medication guide. In general, take it as soon as you remember if it’s close to your usual schedule, or skip and resume your regular dosing day—avoid taking two doses close together.
Zepbound is not typically used together with other GLP‑1 medications. Your clinician will review your current meds and choose one appropriate option rather than combining similar agents.
Medication works best alongside sustainable nutrition and activity habits. Your clinician can help set realistic goals and create a plan that supports long‑term results and maintenance.
Cost and coverage vary by insurance plan and eligibility. Many plans require prior authorization, and out‑of‑pocket pricing can differ by pharmacy. We’ll help you review coverage options and discuss alternatives if needed.
Tirzepatide-based therapy may be used in clinician-guided programs for chronic weight management in appropriate patients, alongside nutrition and physical activity changes.
A clinician must screen for contraindications and risk factors. Patients should disclose current medications, past adverse reactions, pregnancy status, and relevant family history.
Patients must know what symptoms require immediate medical attention (severe or persistent vomiting, dehydration signs, severe abdominal pain, allergic reactions), and how to reach your clinical support.
If compounded: state clearly that compounded drugs are not FDA-approved and are not evaluated by the FDA for safety, effectiveness, or quality prior to marketing.
If medication is provided in a vial, dosing errors are a known risk when patients measure doses themselves. Provide a step-by-step injection basics guide, measurement safety reminders, and “contact your clinician if unsure” instructions.
GLP-1 medications don’t “work” in a single moment—most people experience a timeline of changes.
Many patients notice appetite shifts first: feeling full sooner, less snacking, fewer cravings. Side effects can also appear early, especially nausea or constipation.
Sustainable weight change usually requires consistent use plus lifestyle structure. During this phase, nutrition strategy matters: protein, fiber, hydration, and routines that reduce decision fatigue.
Weight loss is rarely linear. Plateaus are predictable. A plateau often means you need an adjustment in habits, clinical strategy, or expectations—not that “it stopped working.”
Not the scale week-to-week, but the system you can sustain: meals you repeat, movement you can maintain, and a care team you can reach if something feels off.
If you have severe side effects, dehydration symptoms, or you’re considering changing dose timing or amounts, contact your clinician. Do not self-adjust, especially if your medication requires measuring doses.
Nausea is one of the most common early side effects people report on semaglutide-based therapy. The good news: for many patients, it improves as the body adjusts—especially when you use a few practical habits.
Eat smaller meals, slow down, and stop at “comfortably satisfied.” Overeating can feel worse when digestion is slower.
Dehydration can worsen nausea and fatigue. Sip water throughout the day. If your clinician recommends electrolytes, use them strategically.
Many people tolerate bland, protein-forward foods better during the adjustment phase: yogurt, eggs, soups, cooked vegetables, toast, rice, or smoothies (if tolerated).
Very fatty meals, fried foods, and heavy desserts can worsen nausea in some people. If symptoms spike after certain foods, reduce them temporarily.
Some patients find nausea is more noticeable in a predictable window after dosing. Keep meals lighter during that window and avoid large, rich meals.
Severe or persistent vomiting, inability to keep fluids down, or signs of dehydration require medical attention. Don’t self-adjust treatment without clinician input.
